際際滷

際際滷Share a Scribd company logo

Sun pharma ib

Download as PPTX, PDF
SANDESH KADOLE
SANDESH KADOLE

The growth story of Indian biggest pharmaceutical company which is no one in export with all vertical.

1 of 16
Downloaded 29 times
Sun Pharma BY SANDESH KADOLE 1606A1041 VIT MMS III
Sun Pharma Establish in 1983 with five Product by Dilip Shangvi Headquarters is situated in Mumbai, Maharashtra Industry: Pharmaceutical (Recently entered in to power sector) In 1994 Sun pharma was listed on stock exchange 75% of products produced are exported all over the world No. 1 Pharma Company in India and 4th in the world
Sun Pharma Background Sun pharma has ensured world class quality in design, equipment's and operation in all their manufacturing facilities across the world They have 48 ( Finished ) State-of- the art manufacturing site spanning 5 continents These manufacturing units are located in india, The US , Brazine , cannada , Hungary Israle , Bangladesh Mexico, Romania Ireland, mrocco Nigeria South aferica and Malaysia They provide best-inclass products to patients across 150 countries worldwide Successful track record of turning around acquisitions
Worlds 4th Largest Pharma Company US$BL
Sun Pharma at a Glance US Ranked 4th in US*/ Largest Indian Pharma Company in US India No 1 Pharma Company in India Emerging Markets Amongst the Largest Indian Pharma Company in Emerging Markets like brazil Europe Expanding presence in Europe Manufacturing Footprint 42 manufacturing site across the world Market Presence Presence in more than 150 countries across branded and generic markets Operates in about 20+ countries Product Portfolio Portfolio of more than 2000 products across the world with patent Employees 34000+global employee base
Sun Pharma Today More than 426 approved Products by USA FDA Presence in 150 countries across the world Key focus market- Brazil, South Africa, Russia and Emerging market Presence across majority of Western Europe, Canada, Japan Strong product pipeline and Portfolio
Sun pharma ib
Sun pharma ib
Key milestone in USA Entry Strategy FY98 Entry in US through Caraco acquisition FY98-10 Ramp-up in US business FY10 Acquired Taro Pharma Entry into dermatology market FY13 Acquired DUSA - Entry in branded specialty market FY13 Acquired URLs generic business FY14 Acquired Pharmalucence -access to sterile injectable capacity FY15 Acquired InSite Vision Strengthen ophthalmic portfolio FY16 Acquired Ocular Technologies FY17 Acquired Odomzo- branded oncology product from Novartis FY 10 11 Billion FY 17 138 Billion 40% CAGR Sale
Emerging Market Largest Indian Company in Emerging Markets Global footprint Presence in over 100 markets Focus Markets Brazil, Mexico, Russia, Romania, South Africa and complementary & affiliated markets Product Portfolio Extensive basket of branded products, as well as products for retail market Customer Focus Strong relationships with doctors and medical practitioners Sales Force Approximately 2,300 Sales Representatives Opportunity To cross-sell products between Sun Pharma and Ranbaxy marketing infrastructure Japan Entry Acquired 14 established prescription brands from Novartis in March16 Local Manufacturing Across 9 countries and At Canada, Israel and Hungary + Servicing from India facilities Russia Acquisition Acquired Biosintez to enhance presence in Russian market in Nov 16 Gives access to local manufacturing facility
Global Manufacturing Footprint
Global Manufacturing
26% 13% 8% 5% 48% Revenue Base India Market Emerging Market Western Europe & other market API US Maket
USA 2016 President Election Donald Trump elected Obama Health care program closed Make America Great Again Buy American Product US FDA ban on Sun Pharma product and Dadara Plant Introducing multi-layered pricing system for Medicines help for domestic drugs in USA
Sun Pharma in New Strategy Reduce overall dependence on US market Retail Consolidation affecting Margin Slow rete of FDA Approvals and Increased FDA import alerts and Standards Regulation Continue to focus on complex Generics and high entry barrier segments in USA Gain Critical mass in key emerging market and Enhance product basket in emerging markets Improve profitability in developed European market Future market for particular focus will include Latin America, Russian and south Africa and Asian markets Focus on growth markets include Ukraine, Poland, Kazakhstan, Thailand & UAE, Pakistan, Mongolia Acquiring Domestic Companies to access in emerging market Use WTO provision to make USA under pressure
Sun pharma ib

More Related Content

Sun pharma ib

  • 1. Sun Pharma BY SANDESH KADOLE 1606A1041 VIT MMS III
  • 2. Sun Pharma Establish in 1983 with five Product by Dilip Shangvi Headquarters is situated in Mumbai, Maharashtra Industry: Pharmaceutical (Recently entered in to power sector) In 1994 Sun pharma was listed on stock exchange 75% of products produced are exported all over the world No. 1 Pharma Company in India and 4th in the world
  • 3. Sun Pharma Background Sun pharma has ensured world class quality in design, equipment's and operation in all their manufacturing facilities across the world They have 48 ( Finished ) State-of- the art manufacturing site spanning 5 continents These manufacturing units are located in india, The US , Brazine , cannada , Hungary Israle , Bangladesh Mexico, Romania Ireland, mrocco Nigeria South aferica and Malaysia They provide best-inclass products to patients across 150 countries worldwide Successful track record of turning around acquisitions
  • 4. Worlds 4th Largest Pharma Company US$BL
  • 5. Sun Pharma at a Glance US Ranked 4th in US*/ Largest Indian Pharma Company in US India No 1 Pharma Company in India Emerging Markets Amongst the Largest Indian Pharma Company in Emerging Markets like brazil Europe Expanding presence in Europe Manufacturing Footprint 42 manufacturing site across the world Market Presence Presence in more than 150 countries across branded and generic markets Operates in about 20+ countries Product Portfolio Portfolio of more than 2000 products across the world with patent Employees 34000+global employee base
  • 6. Sun Pharma Today More than 426 approved Products by USA FDA Presence in 150 countries across the world Key focus market- Brazil, South Africa, Russia and Emerging market Presence across majority of Western Europe, Canada, Japan Strong product pipeline and Portfolio
  • 9. Key milestone in USA Entry Strategy FY98 Entry in US through Caraco acquisition FY98-10 Ramp-up in US business FY10 Acquired Taro Pharma Entry into dermatology market FY13 Acquired DUSA - Entry in branded specialty market FY13 Acquired URLs generic business FY14 Acquired Pharmalucence -access to sterile injectable capacity FY15 Acquired InSite Vision Strengthen ophthalmic portfolio FY16 Acquired Ocular Technologies FY17 Acquired Odomzo- branded oncology product from Novartis FY 10 11 Billion FY 17 138 Billion 40% CAGR Sale
  • 10. Emerging Market Largest Indian Company in Emerging Markets Global footprint Presence in over 100 markets Focus Markets Brazil, Mexico, Russia, Romania, South Africa and complementary & affiliated markets Product Portfolio Extensive basket of branded products, as well as products for retail market Customer Focus Strong relationships with doctors and medical practitioners Sales Force Approximately 2,300 Sales Representatives Opportunity To cross-sell products between Sun Pharma and Ranbaxy marketing infrastructure Japan Entry Acquired 14 established prescription brands from Novartis in March16 Local Manufacturing Across 9 countries and At Canada, Israel and Hungary + Servicing from India facilities Russia Acquisition Acquired Biosintez to enhance presence in Russian market in Nov 16 Gives access to local manufacturing facility
  • 13. 26% 13% 8% 5% 48% Revenue Base India Market Emerging Market Western Europe & other market API US Maket
  • 14. USA 2016 President Election Donald Trump elected Obama Health care program closed Make America Great Again Buy American Product US FDA ban on Sun Pharma product and Dadara Plant Introducing multi-layered pricing system for Medicines help for domestic drugs in USA
  • 15. Sun Pharma in New Strategy Reduce overall dependence on US market Retail Consolidation affecting Margin Slow rete of FDA Approvals and Increased FDA import alerts and Standards Regulation Continue to focus on complex Generics and high entry barrier segments in USA Gain Critical mass in key emerging market and Enhance product basket in emerging markets Improve profitability in developed European market Future market for particular focus will include Latin America, Russian and south Africa and Asian markets Focus on growth markets include Ukraine, Poland, Kazakhstan, Thailand & UAE, Pakistan, Mongolia Acquiring Domestic Companies to access in emerging market Use WTO provision to make USA under pressure